<DOC>
	<DOCNO>NCT00570830</DOCNO>
	<brief_summary>To review chart data Duke Eye Center determine whether 3-year fluocinolone acetonide sustain drug delivery system ( FA ) safely suppress postoperative inflammation combine phacoemulsification posterior chamber intraocular lens implantation ( phaco/PCIOL ) eye severe uveitis .</brief_summary>
	<brief_title>Retisert Cataract Surgery Patients With Severe Uveitis</brief_title>
	<detailed_description>Cataracts common eye uveitis . It result inflammation use topical systemic steroid . Cataract surgery cause unusually severe inflammatory response , abnormal excessive bleeding , unexpected postoperative IOP responses hypertension hypotony . Previous study show successful outcome preoperative postoperative control intraocular inflammation topical , periocular , systemic steroidal immunosuppressive agent . In patient severe posterior uveitis , periocular intravitreal injection often provide transient effect associate complication hemorrhage , retinal detachment endophthalmitis . Oral corticosteroid therapy also associate side effect multiple organ system body . A novel technology delivers corticosteroid therapy linearly via intravitreal , polymer-coated , sustained release implant develop FDA approve treat severe posterior segment uveitis . FA implantation effectively control inflammation extend period time complicate group patient posterior and/or panuveitis allow reduce immunosuppression . We hope determine whether implant , fluocinolone acetonide sustain drug delivery system ( FA ) , safely suppress postoperative inflammation combine phacoemulsification posterior chamber intraocular lens implantation ( phaco/PCIOL ) eye severe uveitis . We hypothesize combine implant cataract surgery provide good surgical outcome suppress inflammation postoperative period . By review surgical data Duke Eye Center , intend primarily focus safety effectiveness surgical procedure .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Uveitis , Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>A visually significant cataract A history recurrent noninfectious posterior uveitis intermediate uveitis without iridocyclitis incomplete therapeutic response treatmentlimiting side effect oral , periocular corticosteroid , and/or immunosuppressive agent VA least light perception ; Ability comprehend inform consent comply followup examination An allergy fluocinolone acetonide component delivery system A toxoplasmosis scar present study eye , A peripheral retinal detachment ( RD ) area plan fluocinolone acetonide implant placement Required chronic systemic corticosteroid therapy systemic immunosuppressive therapy treat nonocular disease test positive human immunodeficiency virus . Also exclude female patient pregnant lactate take precaution avoid pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>